Cargando…
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to pepti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519899/ https://www.ncbi.nlm.nih.gov/pubmed/31091247 http://dx.doi.org/10.1371/journal.pone.0216781 |
_version_ | 1783418687767707648 |
---|---|
author | Wetz, Christoph Genseke, Philipp Apostolova, Ivayla Furth, Christian Ghazzawi, Sammy Rogasch, Julian M. M. Schatka, Imke Kreissl, Michael C. Hofheinz, Frank Grosser, Oliver S. Amthauer, Holger |
author_facet | Wetz, Christoph Genseke, Philipp Apostolova, Ivayla Furth, Christian Ghazzawi, Sammy Rogasch, Julian M. M. Schatka, Imke Kreissl, Michael C. Hofheinz, Frank Grosser, Oliver S. Amthauer, Holger |
author_sort | Wetz, Christoph |
collection | PubMed |
description | AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we correlated ASP derived form a pre-therapeutic OctreoScan (ASP([In])) and an intra-therapeutic [(177)Lu]-SPECT/CT (ASP([Lu])). MATERIALS AND METHODS: Data from first therapy cycle [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]-DOTATATE)-PRRT was retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46–88] years). The evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions [RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs. NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic ASP was determined with Spearman’s rank correlation coefficient (ρ) and Bland-Altman plots. RESULTS: A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT (PD, median: 11.3, IQR: 8.5–15.5; SD, median: 3.4, IQR: 2.1–4.5; PR, median 1.7, IQR: 0.9–2.8; CR, median: 0.5, IQR: 0.0–1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001) and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sensitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP([In]) and ASP([Lu]) was -0.04 (95% Limits of Agreement, -6.1–6.0). CONCLUSION: Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for therapy monitoring. |
format | Online Article Text |
id | pubmed-6519899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-65198992019-05-31 The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE Wetz, Christoph Genseke, Philipp Apostolova, Ivayla Furth, Christian Ghazzawi, Sammy Rogasch, Julian M. M. Schatka, Imke Kreissl, Michael C. Hofheinz, Frank Grosser, Oliver S. Amthauer, Holger PLoS One Research Article AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we correlated ASP derived form a pre-therapeutic OctreoScan (ASP([In])) and an intra-therapeutic [(177)Lu]-SPECT/CT (ASP([Lu])). MATERIALS AND METHODS: Data from first therapy cycle [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]-DOTATATE)-PRRT was retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46–88] years). The evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions [RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs. NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic ASP was determined with Spearman’s rank correlation coefficient (ρ) and Bland-Altman plots. RESULTS: A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT (PD, median: 11.3, IQR: 8.5–15.5; SD, median: 3.4, IQR: 2.1–4.5; PR, median 1.7, IQR: 0.9–2.8; CR, median: 0.5, IQR: 0.0–1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001) and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sensitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP([In]) and ASP([Lu]) was -0.04 (95% Limits of Agreement, -6.1–6.0). CONCLUSION: Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for therapy monitoring. Public Library of Science 2019-05-15 /pmc/articles/PMC6519899/ /pubmed/31091247 http://dx.doi.org/10.1371/journal.pone.0216781 Text en © 2019 Wetz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wetz, Christoph Genseke, Philipp Apostolova, Ivayla Furth, Christian Ghazzawi, Sammy Rogasch, Julian M. M. Schatka, Imke Kreissl, Michael C. Hofheinz, Frank Grosser, Oliver S. Amthauer, Holger The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title | The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title_full | The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title_fullStr | The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title_full_unstemmed | The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title_short | The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE |
title_sort | association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing prrt with [(177)lu]-dotatate |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519899/ https://www.ncbi.nlm.nih.gov/pubmed/31091247 http://dx.doi.org/10.1371/journal.pone.0216781 |
work_keys_str_mv | AT wetzchristoph theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT gensekephilipp theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT apostolovaivayla theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT furthchristian theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT ghazzawisammy theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT rogaschjulianmm theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT schatkaimke theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT kreisslmichaelc theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT hofheinzfrank theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT grosserolivers theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT amthauerholger theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT wetzchristoph associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT gensekephilipp associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT apostolovaivayla associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT furthchristian associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT ghazzawisammy associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT rogaschjulianmm associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT schatkaimke associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT kreisslmichaelc associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT hofheinzfrank associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT grosserolivers associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate AT amthauerholger associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate |